638217-49-9

Upstream product

• 122536-75-8 Benzyl (3R)-3-[(tert-butoxycarbonyl)amino]pyrrolidine-1-carboxylate 
• 74-88-4 methyl iodide 

Downstream Products

• 917357-84-7 benzyl (3R)-3-[(2-ethoxy-2-oxo-ethyl)(methyl)amino]pyrrolidine-1-carboxylate 
• 917357-85-8 benzyl (3R)-3-[(2-hydroxyethyl)(methyl)amino]pyrrolidine-1-carboxylate 
• 917357-86-9 2-{methyl[(3R)-pyrrolidin-3-yl]amino}ethanol 
• 392338-15-7 tert-butyl [(3R)-pyrrolidin-3-yl]methylcarbamate 
• 917357-83-6 benzyl (3R)-3-(methylamino)-pyrrolidine-1-carboxylate hydrochloride 

Relevant academic research and scientific papers

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

Pyrimidine derivatives

A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.

INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salts or solvates thereof, wherein n, X, Y, R1, R2, R3 and R4 are as described in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating conditions that are mediated by the modulation of 11 βHSD1 , the method comprising administering to a mammal an effective amount of a compound of formula (I).

Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use

The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.